$36.57
1.05% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US45258D1054
Symbol
IMCR

Immunocore Holdings plc - ADR Stock price

$36.57
-2.12 5.48% 1M
+4.56 14.25% 6M
+7.07 23.97% YTD
+7.91 27.60% 1Y
-21.23 36.73% 3Y
+10.57 40.65% 5Y
+10.57 40.65% 10Y
+10.57 40.65% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.38 1.05%
ISIN
US45258D1054
Symbol
IMCR
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.3b
Net debt
positive
Cash
$892.4m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.8 | 4.5
EV/Sales
3.5 | 3.2
EV/FCF
449.7
P/B
4.6
Financial Health
Equity Ratio
35.7%
Return on Equity
-14.2%
ROCE
-4.8%
ROIC
-25.1%
Debt/Equity
1.0
Financials (TTM | estimate)
Revenue
$379.6m | $410.3m
EBITDA
$-41.5m | $-49.3m
EBIT
$-45.1m | $-44.8m
Net Income
$-29.2m | -
Free Cash Flow
$3.0m
Growth (TTM | estimate)
Revenue
-20.2% | 32.3%
EBITDA
61.8% | 25.6%
EBIT
59.2% | 36.4%
Net Income
64.6% | -
Free Cash Flow
-89.3%
Margin (TTM | estimate)
Gross
99.3%
EBITDA
-10.9% | -12.0%
EBIT
-11.9%
Net
-7.7% | -
Free Cash Flow
0.8%
More
EPS
$-0.6
FCF per Share
-
Short interest
23.3%
Employees
493
Rev per Employee
$630.0k
Show more

Is Immunocore Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Immunocore Holdings plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Immunocore Holdings plc - ADR forecast:

18x Buy
78%
4x Hold
17%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Immunocore Holdings plc - ADR forecast:

Buy
78%
Hold
17%
Sell
4%

Financial data from Immunocore Holdings plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
380 380
20% 20%
100%
- Direct Costs 2.71 2.71
21% 21%
1%
377 377
20% 20%
99%
- Selling and Administrative Expenses 165 165
36% 36%
43%
- Research and Development Expense 257 257
21% 21%
68%
-42 -42
62% 62%
-11%
- Depreciation and Amortization 3.60 3.60
72% 72%
1%
EBIT (Operating Income) EBIT -45 -45
59% 59%
-12%
Net Profit -29 -29
65% 65%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Immunocore Holdings plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunocore Holdings plc - ADR Stock News

Neutral
GlobeNewsWire
about 2 months ago
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Positive
Seeking Alpha
about 2 months ago
Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline.
Neutral
GlobeNewsWire
about 2 months ago
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
More Immunocore Holdings plc - ADR News

Company Profile

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Bahija Jallal
Employees 493
Founded 2021
Website www.immunocore.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today